Navigation Links
Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
Date:3/27/2009

- Results to be presented at Israel Society of Nephrology Conference

- EPODURE safety and efficacy now reach 5 months from single treatment

- Data continue to indicate that Biopump may offer alternative to scores of expensive injections

MISGAV, Israel and LONDON, March 27 /PRNewswire/ -- Medgenics (AIM: MEDG) is pleased to announce that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial will be presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

The latest results of the trial show that in the first 2 of the patients treated, the hemoglobin level has now remained continuously in the target range of 10-12 g/dl for more than 5 months following a single EPODURE treatment using the lowest dose of 20 IU/kg/day, thus effectively treating their anemia without receiving any injections of erythropoietin (EPO) during this period. One of the patients received his last EPO injection more than 200 days ago. This is contrasted with the FDA approved standard regimen of thrice weekly EPO injections, in which typical patients would expect to receive up to 85 injections in this timeframe.

A total of 7 patients have now been treated, with 6 patients receiving treatment for more than one month. The seventh patient is the first to receive the higher dose of 40 IU/kg/day, which is double that of the lowest dosage, and the higher dose treatment is proceeding smoothly. There continue to be no adverse events reported in the study. Patient recruitment continues for the higher dose treatment.

The new data will be presented at the conference by Dr. Michal Dranitzki Elhalel, the principal nephrologist of Medgenics' EPODURE Phase I/II clinical trial, currently taking place at the Hadassah Hebrew University Hospital in Jerusalem, Israe
'/>"/>

SOURCE Medgenics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... 26 Brainlab announced the availability of ExacTrac® Infrared Monitoring, ... during radiation therapy treatments, at the American Association of Physicists in ... , , ... tool used by many cancer care centers for patient setup; however, ...
... ,, ROCKVILLE, Md. , July 26 Sequella, Inc., ... announced today the publication of studies in the scientific journal Antimicrobial ... for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: ... Reddy, V.M., L. ...
Cached Medicine Technology:Brainlab Offers Real-Time Monitoring for IGRT 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 3
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
(Date:7/24/2014)... the risk for head and neck cancer (HNC). Evidence suggests ... the risk of HNC in patients with DM has not ... sixth most common type of cancer. It accounts for about ... new cancer cases and 350,000 cancer deaths worldwide each year. ... to examine the risk of HNC in patients with DM. ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3
... -- Despite growing concern about the effects of media ... to be produced and marketed to them. An Indiana ... to their enjoyment of such programs and their characters. ... Media Psychology , Andrew J. Weaver, an assistant ...
... Wong, one of the nation,s foremost experts on aging, ... on Aging of the National Institutes of Health to ... the grant for a longitudinal aging study she and ... will collect current data from thousands of participants and ...
... primary language is not English, patient navigators may help improve ... the May 23 issue of Archives of Internal Medicine ... of the journal,s Health Care Reform series. According to ... country,s main causes of cancer deaths. "Nevertheless," the authors write, ...
... -- New research suggests that a certain class of drugs ... risk that male patients will be unable to urinate. ... blockage in the body,s air passages, affects an estimated 10 ... class of drugs called "inhaled anticholinergic" medications are used to ...
... 2011More than eight of 10 leaders in health and ... to implement key provisions of the Affordable Care Act ... outlined in the law. Such key provisions include expanding ... insurance exchanges with premium subsidies. Findings are from the ...
... MONDAY, May 23 (HealthDay News) -- U.S. researchers have ... diseases, which are rare, progressive conditions that affect brain ... and bovine spongiform encephalopathy, commonly known as "mad cow ... of the Journal of the American Dietetic Association ...
Cached Medicine News:Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 2Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 3Health News:UTMB researcher receives $3 million NIH grant to study aging in Mexico 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 3Health News:Certain COPD Meds Linked to Urinary Troubles in Men 2Health News:States should be allowed to implement key health reform law provisions early, experts say 2Health News:States should be allowed to implement key health reform law provisions early, experts say 3Health News:CDC Warns Against Exposure to 'Mad Cow'-Like Brain Diseases 2
... airways., ,When a difficult airway must ... Now you can be assured of rapid ... Esophageal/Tracheal double-Lumen Airway from Nellcor. Unlike traditional ... to establish a nonsurgical patient airway when ...
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile and individually bagged....
Medicine Products: